Healionics is commercializing a synthetic vascular graft (STARgraft) with superior patency (ability to maintain blood flow), based on our platform STAR biomaterial technology.  The graft will initially address the urgent need for improved vascular access for hemodialysis patients, with subsequent applications to peripheral artery disease, vascular trauma, and potentially coronary artery bypass. We are also developing a device to enable needle-free hemodialysis (STARport).


All implanted devices – including prosthetics, ophthalmic, surgical products, sensors, therapeutics delivery, stimulators, percutaneous devices, vascular – share two common problems:

  • The body reacts to the implant and scars the surrounding tissue, causing medical issues, damaging the device and/or degrading its function.
  • Infection is common, hard to control, and expensive to treat.

Our STAR material has demonstrated substantial benefits in a variety of implantable applications, including the ability to impart high resistance to infection and scarring / fibrous encapsulation, and strong promotion of angiogenesis – thereby improving overall biointegration with host tissue.

Licensing opportunities will be considered. If you have an implantable device in development or production, inquiries are welcome.

For examples of applications that have been investigated, click here.